Molecular Mechanism of Sirtuin 1 Modulation by the AROS Protein

The protein lysine deacylases of the NAD+-dependent Sirtuin family contribute to metabolic regulation, stress responses, and aging processes, and the human Sirtuin isoforms, Sirt1-7, are considered drug targets for aging-related diseases. The nuclear isoform Sirt1 deacetylates histones and transcription factors to regulate, e.g., metabolic adaptations and circadian mechanisms, and it is used as a therapeutic target for Huntington’s disease and psoriasis. Sirt1 is regulated through a multitude of mechanisms, including the interaction with regulatory proteins such as the inhibitors Tat and Dbc1 or the activator AROS. Here, we describe a molecular characterization of AROS and how it regulates Sirt1. We find that AROS is a partly intrinsically disordered protein (IDP) that inhibits rather than activates Sirt1. A biochemical characterization of the interaction including binding and stability assays, NMR spectroscopy, mass spectrometry, and a crystal structure of Sirtuin/AROS peptide complex reveal that AROS acts as a competitive inhibitor, through binding to the Sirt1 substrate peptide site. Our results provide molecular insights in the physiological regulation of Sirt1 by a regulator protein and suggest the peptide site as an opportunity for Sirt1-targeted drug development.

[1]  D. Sinclair,et al.  Sirtuin activators and inhibitors: Promises, achievements, and challenges. , 2018, Pharmacology & therapeutics.

[2]  M. Weiss,et al.  The MX beamlines BL14.1-3 at BESSY II , 2016 .

[3]  Utz Fischer,et al.  ProteoPlex: stability optimization of macromolecular complexes by sparse-matrix screening of chemical space , 2015, Nature Methods.

[4]  David T. Jones,et al.  DISOPRED3: precise disordered region predictions with annotated protein-binding activity , 2014, Bioinform..

[5]  T. Suuronen,et al.  AROS has a context‐dependent effect on SIRT1 , 2014, FEBS letters.

[6]  F. Jiang,et al.  Crystallographic structure of a small molecule SIRT1 activator-enzyme complex , 2014, Nature Communications.

[7]  C. Steegborn,et al.  New assays and approaches for discovery and design of Sirtuin modulators , 2014, Expert opinion on drug discovery.

[8]  J. Milner,et al.  Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity , 2013, Open Biology.

[9]  Frank Fischer,et al.  An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms , 2013, Nature Communications.

[10]  S. Moniot,et al.  Crystal structure analysis of human Sirt2 and its ADP-ribose complex. , 2013, Journal of structural biology.

[11]  S. Mosalaganti,et al.  Molecular architecture of the human protein deacetylase Sirt1 and its regulation by AROS and resveratrol , 2013, Bioscience reports.

[12]  B. Morris.  Seven sirtuins for seven deadly diseases of aging. , 2013, Free radical biology & medicine.

[13]  C. Steegborn,et al.  Sirt1 activation by resveratrol is substrate sequence-selective , 2013, Aging.

[14]  G. Donmez,et al.  SIRT1 and SIRT2: emerging targets in neurodegeneration , 2013, EMBO molecular medicine.

[15]  D. Wolters,et al.  A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol , 2012, PloS one.

[16]  F. Jiang,et al.  Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5. , 2012, The Journal of organic chemistry.

[17]  Jian Peng,et al.  Template-based protein structure modeling using the RaptorX web server , 2012, Nature Protocols.

[18]  Michael Krug,et al.  XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS , 2012 .

[19]  R. Marmorstein,et al.  SIRT1 Contains N- and C-terminal Regions That Potentiate Deacetylase Activity* , 2011, The Journal of Biological Chemistry.

[20]  Young-Sang Jung,et al.  Peptide switch is essential for Sirt1 deacetylase activity. , 2011, Molecular cell.

[21]  C. Steegborn,et al.  Structure-based development of novel sirtuin inhibitors , 2011, Aging.

[22]  D. Petersen,et al.  The human sirtuin family: Evolutionary divergences and functions , 2011, Human Genomics.

[23]  C. Wolberger,et al.  Structure of Sir2Tm bound to a propionylated peptide , 2011, Protein science : a publication of the Protein Society.

[24]  J. Bergquist,et al.  Cloud-point extraction and delipidation of porcine brain proteins in combination with bottom-up mass spectrometry approaches for proteome analysis. , 2010, Journal of proteome research.

[25]  R. Marmorstein,et al.  Structural basis for sirtuin function: what we know and what we don't. , 2010, Biochimica et biophysica acta.

[26]  Wentao Wei,et al.  Crystal Structures of Human SIRT3 Displaying Substrate-induced Conformational Changes , 2009, The Journal of Biological Chemistry.

[27]  Junjie Chen,et al.  DBC1 is a negative regulator of SIRT1 , 2008, Nature.

[28]  J. Qin,et al.  Negative regulation of the deacetylase SIRT1 by DBC1 , 2008, Nature.

[29]  S. Um,et al.  Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. , 2007, Molecular cell.

[30]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[31]  Tatsuo Tanaka,et al.  A novel nucleolar protein interacts with ribosomal protein S19. , 2006, Biochemical and biophysical research communications.

[32]  Angelika Pedal,et al.  SIRT1 Regulates HIV Transcription via Tat Deacetylation , 2005, PLoS biology.

[33]  D T Jones,et al.  Protein secondary structure prediction based on position-specific scoring matrices. , 1999, Journal of molecular biology.

[34]  J. Tuls,et al.  Peptide alpha-helicity in aqueous trifluoroethanol: correlations with predicted alpha-helicity and the secondary structure of the corresponding regions of bovine growth hormone. , 1990, Biochemistry.

[35]  P E Wright,et al.  Folding of immunogenic peptide fragments of proteins in water solution. II. The nascent helix. , 1988, Journal of molecular biology.

[36]  R. Sternglanz,et al.  Structural basis for allosteric stimulation of Sir2 activity by Sir4 binding. , 2013, Genes & development.

[37]  P. Afonine,et al.  research papers Acta Crystallographica Section D Biological , 2003 .

[38]  Vincent B. Chen,et al.  Acta Crystallographica Section D Biological , 2001 .

[39]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[40]  E Schwarz,et al.  Inhibition of aggregation side reactions during in vitro protein folding. , 1999, Methods in enzymology.